{"transactions":[{"id":711982,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-09T20:47:48.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":85918,"price":44.86,"value":3854281.48,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2469959,"source":{"system":"sec-edgar","filing":"0000947871-26-000695","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787126000695/ownership.xml","form_type":"4"}},{"id":718644,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:45:31.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":115844,"price":45.5,"value":5270902.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2555877,"source":{"system":"sec-edgar","filing":"0000947871-26-000684","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787126000684/ownership.xml","form_type":"4"}},{"id":725473,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:15:15.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001357522-26-000005","document":"form4-06262026_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000135752226000005/form4-06262026_040608.xml","form_type":"4"}},{"id":732426,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-18T21:45:51.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":17340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":17340,"derivative":{"exercise_price":36.73,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":17340},"source":{"system":"sec-edgar","filing":"0001357522-26-000003","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000135752226000003/edgardoc.xml","form_type":"4"}},{"id":734153,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T20:49:30.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder."}],"balance_after":16377,"derivative":{"exercise_price":35.59,"exercise_date":"2027-06-02","expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":16377},"source":{"system":"sec-edgar","filing":"0001357522-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000135752226000001/primarydocument.xml","form_type":"4"}},{"id":737551,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T21:06:45.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP.  As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":15000,"derivative":{"exercise_price":11.6,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-26-000220","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000161071726000220/form4.xml","form_type":"4"}},{"id":759000,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-30T01:02:49.000Z","date":"2026-05-27","kind":"sale","planned":true,"acquired":false,"shares":101,"price":44.49,"value":4493.49,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2671721,"source":{"system":"sec-edgar","filing":"0000947871-26-000588","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787126000588/ownership.xml","form_type":"4"}},{"id":785054,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T23:14:02.000Z","date":"2026-05-11","kind":"sale","planned":true,"acquired":false,"shares":184639,"price":46.22,"value":8534014.58,"ownership":{"direct":false,"nature":"See footnotes("},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2671822,"source":{"system":"sec-edgar","filing":"0000947871-26-000518","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787126000518/ownership.xml","form_type":"4"}},{"id":785053,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T23:14:02.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":59767,"price":44.58,"value":2664412.86,"ownership":{"direct":false,"nature":"See footnotes("},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2856461,"source":{"system":"sec-edgar","filing":"0000947871-26-000518","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787126000518/ownership.xml","form_type":"4"}},{"id":785052,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T23:14:02.000Z","date":"2026-05-07","kind":"sale","planned":true,"acquired":false,"shares":48546,"price":44.61,"value":2165637.06,"ownership":{"direct":false,"nature":"See footnotes("},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2916228,"source":{"system":"sec-edgar","filing":"0000947871-26-000518","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787126000518/ownership.xml","form_type":"4"}},{"id":803837,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T00:42:23.000Z","date":"2026-04-18","kind":"sale","planned":true,"acquired":false,"shares":2948,"price":44.52,"value":131244.96,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2964774,"source":{"system":"sec-edgar","filing":"0000947871-26-000459","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787126000459/ownership.xml","form_type":"4"}},{"id":803836,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T00:42:23.000Z","date":"2026-04-17","kind":"sale","planned":true,"acquired":false,"shares":52397,"price":44.68,"value":2341097.96,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2967722,"source":{"system":"sec-edgar","filing":"0000947871-26-000459","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787126000459/ownership.xml","form_type":"4"}},{"id":807373,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-16T23:15:05.000Z","date":"2026-04-16","kind":"sale","planned":true,"acquired":false,"shares":226906,"price":45.34,"value":10287918.04,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3020119,"source":{"system":"sec-edgar","filing":"0000947871-26-000447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787126000447/ownership.xml","form_type":"4"}},{"id":807372,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-16T23:15:05.000Z","date":"2026-04-15","kind":"sale","planned":true,"acquired":false,"shares":235863,"price":44.64,"value":10528924.32,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3247025,"source":{"system":"sec-edgar","filing":"0000947871-26-000447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787126000447/ownership.xml","form_type":"4"}},{"id":807371,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-16T23:15:05.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":47814,"price":44.51,"value":2128201.14,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3482888,"source":{"system":"sec-edgar","filing":"0000947871-26-000447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787126000447/ownership.xml","form_type":"4"}},{"id":919726,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-05T00:43:55.000Z","date":"2026-02-03","kind":"sale","planned":true,"acquired":false,"shares":29063,"price":44.58,"value":1295628.54,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3530702,"source":{"system":"sec-edgar","filing":"0000947871-26-000089","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787126000089/ownership.xml","form_type":"4"}},{"id":919725,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-05T00:43:55.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":1890,"price":44.57,"value":84237.3,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3559765,"source":{"system":"sec-edgar","filing":"0000947871-26-000089","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787126000089/ownership.xml","form_type":"4"}},{"id":926838,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2.12,"expiration_date":"2024-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926837,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926836,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926835,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.965,"expiration_date":"2032-08-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926834,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.9899,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926833,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2.6,"expiration_date":"2031-09-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926832,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2.74,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926831,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.27,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926830,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":2,"expiration_date":"2030-03-19","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926829,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.61,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926828,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":12.5,"expiration_date":"2028-06-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926827,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2018 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":9.7,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926826,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from March 22, 2016, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2026-03-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926825,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":2.12,"value":31800.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":210000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926824,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":1.64,"value":24600.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":195000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926823,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":2.49,"value":37350.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":180000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926822,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":0.965,"value":14475.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":165000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926821,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":0.9899,"value":14848.5,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926820,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":2.6,"value":39000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":135000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926819,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":2.74,"value":41100.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":120000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926818,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":3.27,"value":49050.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":105000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926817,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":2,"value":30000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926816,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":3.61,"value":54150.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926815,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":12.5,"value":187500.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926814,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":9.7,"value":145500.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":926813,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-30T23:39:04.000Z","date":"2026-01-28","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":15,"value":450000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0000947871-26-000079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787126000079/ownership.xml","form_type":"4"}},{"id":958467,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-30T01:42:07.000Z","date":"2025-12-24","kind":"sale","planned":true,"acquired":false,"shares":33356,"price":44.55,"value":1486009.8,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3561655,"source":{"system":"sec-edgar","filing":"0000947871-25-001095","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787125001095/ownership.xml","form_type":"4"}},{"id":962235,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-20T00:24:52.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":875,"price":44.49,"value":38928.75,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3595011,"source":{"system":"sec-edgar","filing":"0000947871-25-001087","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787125001087/ownership.xml","form_type":"4"}},{"id":962234,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-20T00:24:52.000Z","date":"2025-12-18","kind":"sale","planned":true,"acquired":false,"shares":100,"price":44.49,"value":4449.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3595886,"source":{"system":"sec-edgar","filing":"0000947871-25-001087","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787125001087/ownership.xml","form_type":"4"}},{"id":962233,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-20T00:24:52.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":900,"price":44.5,"value":40050.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3595986,"source":{"system":"sec-edgar","filing":"0000947871-25-001087","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787125001087/ownership.xml","form_type":"4"}},{"id":987378,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T23:41:57.000Z","date":"2025-11-26","kind":"sale","planned":true,"acquired":false,"shares":1600,"price":44.49,"value":71184.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3596886,"source":{"system":"sec-edgar","filing":"0000947871-25-001044","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787125001044/ownership.xml","form_type":"4"}},{"id":987377,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T23:41:57.000Z","date":"2025-11-25","kind":"sale","planned":true,"acquired":false,"shares":11890,"price":44.6,"value":530294.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3598486,"source":{"system":"sec-edgar","filing":"0000947871-25-001044","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787125001044/ownership.xml","form_type":"4"}},{"id":987376,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T23:41:57.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":94583,"price":44.54,"value":4212726.82,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3610376,"source":{"system":"sec-edgar","filing":"0000947871-25-001044","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000094787125001044/ownership.xml","form_type":"4"}},{"id":1097639,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2025-07-02T01:17:05.000Z","date":"2025-06-27","kind":"other","planned":false,"acquired":false,"shares":1397684,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.5,"exercise_date":"2025-04-29","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":1397684},"source":{"system":"sec-edgar","filing":"0000947871-25-000635","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787125000635/ownership.xml","form_type":"4"}},{"id":1097638,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T01:17:05.000Z","date":"2025-06-27","kind":"sale","planned":false,"acquired":false,"shares":1176332,"price":4.1586,"value":4891894.2552,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 27, 2025, OrbiMed Private Investments V, LP (\"OPI V\") exercised common warrants (\"Warrants\") to purchase 1,397,684 shares of the Issuer's Common Stock for $3.50 per share. OPI V paid the exercise price on a cashless basis, resulting in the Issuer withholding 1,176,332 of the Warrant shares to pay the exercise price and issuing to OPI V the remaining 221,352 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7165006,"source":{"system":"sec-edgar","filing":"0000947871-25-000635","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787125000635/ownership.xml","form_type":"4"}},{"id":1097637,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T01:17:05.000Z","date":"2025-06-27","kind":"other","planned":false,"acquired":true,"shares":1397684,"price":3.5,"value":4891894.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8341338,"source":{"system":"sec-edgar","filing":"0000947871-25-000635","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787125000635/ownership.xml","form_type":"4"}},{"id":1100214,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-27T20:30:15.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-018387","document":"form4-06272025_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925018387/form4-06272025_040612.xml","form_type":"4"}},{"id":1106346,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T23:36:14.000Z","date":"2025-06-16","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders."}],"balance_after":30000,"derivative":{"exercise_price":14.68,"exercise_date":"2026-06-16","expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-25-004956","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000156218025004956/primarydocument.xml","form_type":"4"}},{"id":1110096,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-16T21:08:24.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":19959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provide to OrbiMed Private Investments VIII, LP."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in full upon the earlier of June 12, 2026 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":19959,"derivative":{"exercise_price":16.99,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":19959},"source":{"system":"sec-edgar","filing":"0002036042-25-000033","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000203604225000033/edgardoc.xml","form_type":"4"}},{"id":1109516,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:26:41.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP."}],"balance_after":15000,"derivative":{"exercise_price":4.24,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-25-000230","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000161071725000230/form4.xml","form_type":"4"}},{"id":1177663,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-04T23:42:30.000Z","date":"2025-04-03","kind":"purchase","planned":false,"acquired":true,"shares":124193,"price":20.13,"value":2500005.09,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of the Issuer's common stock were purchased in an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":443792,"source":{"system":"sec-edgar","filing":"0000947871-25-000360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000094787125000360/ownership.xml","form_type":"4"}},{"id":1177662,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-04T23:42:30.000Z","date":"2025-04-03","kind":"purchase","planned":false,"acquired":true,"shares":372578,"price":20.13,"value":7499995.14,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of the Issuer's common stock were purchased in an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14809075,"source":{"system":"sec-edgar","filing":"0000947871-25-000360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000094787125000360/ownership.xml","form_type":"4"}},{"id":1276905,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C convertible preferred stock","published_at":"2025-02-10T21:05:06.000Z","date":"2025-02-10","kind":"exercise","planned":false,"acquired":false,"shares":2048760,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments VIII, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Advisors, GP VIII and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1402204},"source":{"system":"sec-edgar","filing":"0000950170-25-017031","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000095017025017031/ownership.xml","form_type":"4"}},{"id":1276904,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2025-02-10T21:05:06.000Z","date":"2025-02-10","kind":"exercise","planned":false,"acquired":false,"shares":2560951,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments VIII, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Advisors, GP VIII and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1752755},"source":{"system":"sec-edgar","filing":"0000950170-25-017031","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000095017025017031/ownership.xml","form_type":"4"}},{"id":1276903,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-10T21:05:06.000Z","date":"2025-02-10","kind":"purchase","planned":false,"acquired":true,"shares":550000,"price":18,"value":9900000.0,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments VIII, LP"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Reflects shares purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Advisors, GP VIII and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3704959,"source":{"system":"sec-edgar","filing":"0000950170-25-017031","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000095017025017031/ownership.xml","form_type":"4"}},{"id":1276902,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-10T21:05:06.000Z","date":"2025-02-10","kind":"exercise","planned":false,"acquired":true,"shares":3154959,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments VIII, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Advisors, GP VIII and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3154959,"source":{"system":"sec-edgar","filing":"0000950170-25-017031","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000095017025017031/ownership.xml","form_type":"4"}},{"id":1420872,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-28T20:30:07.000Z","date":"2024-08-26","kind":"sale","planned":false,"acquired":false,"shares":83695,"price":13,"value":1088035.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $12.59 to a high of $13.35 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VI, or OrbiMed Capital is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000729","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000094787124000729/ownership.xml","form_type":"4"}},{"id":1424251,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-23T22:41:21.000Z","date":"2024-08-23","kind":"sale","planned":false,"acquired":false,"shares":69500,"price":13.03,"value":905585.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $12.80 to a high of $13.20 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VI, or OrbiMed Capital is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":83695,"source":{"system":"sec-edgar","filing":"0000947871-24-000721","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000094787124000721/ownership.xml","form_type":"4"}},{"id":1424250,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-23T22:41:21.000Z","date":"2024-08-22","kind":"sale","planned":false,"acquired":false,"shares":391482,"price":12.94,"value":5065777.08,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $12.765 to a high of $13.475 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VI, or OrbiMed Capital is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":153195,"source":{"system":"sec-edgar","filing":"0000947871-24-000721","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000094787124000721/ownership.xml","form_type":"4"}},{"id":1424249,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-23T22:41:21.000Z","date":"2024-08-21","kind":"sale","planned":false,"acquired":false,"shares":13300,"price":14.61,"value":194313.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $14.605 to a high of $14.615 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VI, or OrbiMed Capital is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":544677,"source":{"system":"sec-edgar","filing":"0000947871-24-000721","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000094787124000721/ownership.xml","form_type":"4"}},{"id":1424248,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-23T22:41:21.000Z","date":"2024-08-21","kind":"sale","planned":false,"acquired":false,"shares":394400,"price":13.52,"value":5332288.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $13.30 to a high of $13.925 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors LLC (\"OrbiMed Advisors\"). OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VI, or OrbiMed Capital is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":557977,"source":{"system":"sec-edgar","filing":"0000947871-24-000721","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000094787124000721/ownership.xml","form_type":"4"}},{"id":1470697,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-24T21:00:11.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 20, 2025 or the date of the Issuer's 2025 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP."}],"balance_after":40000,"derivative":{"exercise_price":7.73,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-018011","document":"form4-06242024_050604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924018011/form4-06242024_050604.xml","form_type":"4"}},{"id":1476982,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T20:41:58.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Pursuant to an agreement with Advisors and GP V, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OPI V."}],"balance_after":15000,"derivative":{"exercise_price":2.12,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-24-000340","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000161071724000340/form4.xml","form_type":"4"}},{"id":1482131,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-12T23:33:48.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":20594,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options granted on June 10, 2024 will become vested on the earlier of (i) June 10, 2025 or (ii) the business day prior to the date of the 2025 annual meeting of stockholders."}],"balance_after":20594,"derivative":{"exercise_price":17.13,"exercise_date":"2025-06-10","expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":20594},"source":{"system":"sec-edgar","filing":"0001562180-24-005022","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000156218024005022/primarydocument.xml","form_type":"4"}},{"id":1508676,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:09:42.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"(Continued from Footnote 8) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"1/12 of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Person, GP VI, Genesis GP and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":19,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001626199-24-000096","document":"wk-form4_1716250169.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000162619924000096/wk-form4_1716250169.xml","form_type":"4"}},{"id":1508675,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:09:42.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"(Continued from Footnote 8) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Person, GP VI, Genesis GP and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":7.43,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-24-000096","document":"wk-form4_1716250169.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000162619924000096/wk-form4_1716250169.xml","form_type":"4"}},{"id":1508674,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:09:42.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"(Continued from Footnote 8) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Person, GP VI, Genesis GP and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":13.89,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-24-000096","document":"wk-form4_1716250169.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000162619924000096/wk-form4_1716250169.xml","form_type":"4"}},{"id":1508673,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:09:42.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"(Continued from Footnote 8) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Person, GP VI, Genesis GP and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":13.45,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000096","document":"wk-form4_1716250169.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000162619924000096/wk-form4_1716250169.xml","form_type":"4"}},{"id":1508672,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:09:42.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"(Continued from Footnote 8) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Person, GP VI, Genesis GP and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.6233,"expiration_date":"2030-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000096","document":"wk-form4_1716250169.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000162619924000096/wk-form4_1716250169.xml","form_type":"4"}},{"id":1508671,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:09:42.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"(Continued from Footnote 8) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Person, GP VI, Genesis GP and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":4.09,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000096","document":"wk-form4_1716250169.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000162619924000096/wk-form4_1716250169.xml","form_type":"4"}},{"id":1508670,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:09:42.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"(Continued from Footnote 8) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Person, GP VI, Genesis GP and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":11.31,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000096","document":"wk-form4_1716250169.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000162619924000096/wk-form4_1716250169.xml","form_type":"4"}},{"id":1508669,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T00:09:42.000Z","date":"2024-05-18","kind":"other","planned":false,"acquired":false,"shares":264315,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Company Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, GP VI, Genesis GP and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-24-000096","document":"wk-form4_1716250169.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000162619924000096/wk-form4_1716250169.xml","form_type":"4"}},{"id":1508668,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T00:09:42.000Z","date":"2024-05-18","kind":"other","planned":false,"acquired":false,"shares":2416181,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Company Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, GP VI, Genesis GP and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-24-000096","document":"wk-form4_1716250169.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000162619924000096/wk-form4_1716250169.xml","form_type":"4"}},{"id":1523075,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2024-05-09T00:34:00.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":1397684,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Issued at no additional consideration to OPI V in connection with its subscription of Pre-Funded Warrants for shares of the Issuer's Common Stock at a price of $1.7311."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the terms and conditions set forth in the Common Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Common Warrant until it has been exercised in full. The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder, together with OrbiMed Advisors and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Common Warrants beneficially owned by OrbiMed Advisors are not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the terms and conditions set forth in the Common Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Common Warrant until it has been exercised in full. The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder, together with OrbiMed Advisors and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Common Warrants beneficially owned by OrbiMed Advisors are not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors, a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is a member of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1397684,"derivative":{"exercise_price":3.5,"underlying":"Common Stock","underlying_shares":1397684},"source":{"system":"sec-edgar","filing":"0000947871-24-000451","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787124000451/ownership.xml","form_type":"4"}},{"id":1523074,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2024-05-09T00:34:00.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":1444085,"price":1.7311,"value":2499855.5435,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Pre-Funded Warrant until it has been exercised in full. The Pre-Funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-Funded Warrants beneficially owned by OrbiMed Advisors are not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Pre-Funded Warrant until it has been exercised in full. The Pre-Funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with OrbiMed Advisors LLC (\"OrbiMed Advisors\") and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-Funded Warrants beneficially owned by OrbiMed Advisors are not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors, a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is a member of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1444085,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1444085},"source":{"system":"sec-edgar","filing":"0000947871-24-000451","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787124000451/ownership.xml","form_type":"4"}},{"id":1670954,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-25T21:32:07.000Z","date":"2024-01-23","kind":"purchase","planned":false,"acquired":true,"shares":454545,"price":11,"value":4999995.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of the Issuer's common stock were purchased in an underwritten registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14436497,"source":{"system":"sec-edgar","filing":"0000947871-24-000070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000094787124000070/ownership.xml","form_type":"4"}},{"id":1678996,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-01-16T21:36:56.000Z","date":"2024-01-11","kind":"other","planned":false,"acquired":false,"shares":145251,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":12.74,"exercise_date":"2019-01-18","expiration_date":"2024-01-18","underlying":"Common Stock","underlying_shares":145251},"source":{"system":"sec-edgar","filing":"0000947871-24-000033","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787124000033/ownership.xml","form_type":"4"}},{"id":1678995,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-16T21:36:56.000Z","date":"2024-01-11","kind":"other","planned":false,"acquired":true,"shares":145251,"price":12.74,"value":1850497.74,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2416181,"source":{"system":"sec-edgar","filing":"0000947871-24-000033","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787124000033/ownership.xml","form_type":"4"}},{"id":1687208,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-05T00:02:25.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12 of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP."}],"balance_after":17500,"derivative":{"exercise_price":19,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001626199-24-000009","document":"wk-form4_1704412934.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000162619924000009/wk-form4_1704412934.xml","form_type":"4"}},{"id":1697810,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T21:20:45.000Z","date":"2023-12-28","kind":"sale","planned":false,"acquired":false,"shares":139166,"price":18.32,"value":2549521.12,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":264315,"source":{"system":"sec-edgar","filing":"0000947871-23-001190","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787123001190/ownership.xml","form_type":"4"}},{"id":1697809,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T21:20:45.000Z","date":"2023-12-28","kind":"sale","planned":false,"acquired":false,"shares":1195683,"price":18.32,"value":21904912.56,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2270930,"source":{"system":"sec-edgar","filing":"0000947871-23-001190","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787123001190/ownership.xml","form_type":"4"}},{"id":1697808,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T21:20:45.000Z","date":"2023-12-28","kind":"sale","planned":false,"acquired":false,"shares":3128,"price":19.82,"value":61996.96,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":403481,"source":{"system":"sec-edgar","filing":"0000947871-23-001190","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787123001190/ownership.xml","form_type":"4"}},{"id":1697807,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T21:20:45.000Z","date":"2023-12-28","kind":"sale","planned":false,"acquired":false,"shares":26872,"price":19.82,"value":532603.04,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3466613,"source":{"system":"sec-edgar","filing":"0000947871-23-001190","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787123001190/ownership.xml","form_type":"4"}},{"id":1697806,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T21:20:45.000Z","date":"2023-12-27","kind":"sale","planned":false,"acquired":false,"shares":18922,"price":19.96,"value":377683.12,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":406609,"source":{"system":"sec-edgar","filing":"0000947871-23-001190","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787123001190/ownership.xml","form_type":"4"}},{"id":1697805,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T21:20:45.000Z","date":"2023-12-27","kind":"sale","planned":false,"acquired":false,"shares":162576,"price":19.96,"value":3245016.96,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3493485,"source":{"system":"sec-edgar","filing":"0000947871-23-001190","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000094787123001190/ownership.xml","form_type":"4"}},{"id":1717582,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T21:02:31.000Z","date":"2023-12-06","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000386","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000161071723000386/form4.xml","form_type":"4"}},{"id":1791982,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-31T21:18:44.000Z","date":"2023-08-29","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":6.2,"value":3100000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of the Issuer's common stock were purchased in a private transaction pursuant to the terms of a Stock Purchase Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VI, and OrbiMed Capital is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8019187,"source":{"system":"sec-edgar","filing":"0000947871-23-000914","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000094787123000914/ownership.xml","form_type":"4"}},{"id":1842706,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-29T01:00:39.000Z","date":"2023-06-27","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 27, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":6.5,"expiration_date":"2033-06-26","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-040111","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919123040111/doc4.xml","form_type":"4"}},{"id":1849045,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T21:03:54.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP."}],"balance_after":15000,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000189","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000161071723000189/form4.xml","form_type":"4"}},{"id":1855949,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T23:29:50.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":22123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options granted on June 12, 2023 will become vested on the earlier of (i) June 12, 2024 or (ii) the business day prior to the date of the 2024 annual meeting of stockholders."}],"balance_after":22123,"derivative":{"exercise_price":9.55,"exercise_date":"2024-06-12","expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":22123},"source":{"system":"sec-edgar","filing":"0001562180-23-005177","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000156218023005177/primarydocument.xml","form_type":"4"}},{"id":2061939,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-01-06T00:07:41.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 3, 2023 and 1/12 of the shares subject to the option shall vest monthly thereafter."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP."}],"balance_after":10000,"derivative":{"exercise_price":7.43,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-23-000024","document":"wf-form4_167296364304748.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000162619923000024/wf-form4_167296364304748.xml","form_type":"4"}},{"id":2157400,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-16T20:34:16.000Z","date":"2022-09-16","kind":"purchase","acquired":true,"shares":484496,"price":10.32,"value":4999998.72,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Shares are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, GP VI, OrbiMed Advisors, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI, OrbiMed Advisors, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":13981952,"source":{"system":"sec-edgar","filing":"0000947871-22-000973","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000094787122000973/ownership.xml","form_type":"4"}},{"id":2185385,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-15T22:47:25.000Z","date":"2022-08-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The Reporting Person is obligated to transfer any shares issued pursuant to any equity grants made to him by the Issuer, or the economic benefits thereof, to Advisors and certain of its related entities. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":15000,"derivative":{"exercise_price":0.965,"expiration_date":"2032-08-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-016289","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357522/000156761922016289/doc1.xml","form_type":"4"}}],"next_cursor":"2022-08-15T22:47:25.000000Z,2185385"}